CD274 and non-small cell lung carcinoma: Initial searches for predictive markers focused on the expression of PD-L1 [8, 9], but despite FDA approval for patient stratification based on PD-L1 expression in primary tumor tissue of NSCLC patients, interpretation of such immune stainings with respect to cell type and optimal cut off percentage remains challenging [10, 11].